RecruitingNCT06441669
Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT
Effect of Letermovir Prophylaxis on Cytomegalovirus-specific Immune Reconstitution Post Unrelated Cord Blood Transplantation
Sponsor
Anhui Provincial Hospital
Enrollment
60 participants
Start Date
May 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation
Eligibility
Inclusion Criteria2
- Patients are receiving a first unrelated cord blood transplantation (UCBT).
- Patients start letemovir prophylaxis within 0-28 days post UCBT.
Exclusion Criteria2
- Patients having active CMV DNAemia at the time of letermovir initiation.
- Patients recruited in a clinical study on an anti-CMV trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLetermovir
Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06441669